Search results
Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III
Zacks via Yahoo Finance· 5 months agoRoche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone...
Roche (RHHBY) Tecentriq SC Receives Positive CHMP Opinion
Zacks via Yahoo Finance· 6 months agoRoche RHHBY announced that the European Medicines Agency’s Committee for Medicinal Products for...
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
Zacks via Yahoo Finance· 2 years agoSwiss pharma giant Roche Holding AG’s RHHBY third-quarter revenues declined 6% to CHF 14.7 billion...
Top 15 Best-Selling Cancer Drugs
Insider Monkey via Yahoo Finance· 4 months agoIn this article, we will be discussing the top 15 best-selling cancer drugs. If you are not interested in reading about the global cancer treatment...
Genentech's Tecentriq Plus Avastin Combo Cuts Risk of Cancer Returning In Early-Stage Liver Cancer
Benzinga via Yahoo Finance· 1 year agoGenentech, a unit of Roche Holdings AG (OTC: RHHBY), announced that the Phase 3 IMbrave050 study met...
Roche (RHHBY) Announces Data on Tecentriq Combo for HCC
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of...
Roche (RHHBY) 1H Revenues, Earnings Down on Lower COVID-19 Test Sales
Zacks via Yahoo Finance· 10 months agoRoche Holding AG’s RHHBY performance in the first half was average, as COVID-19 product related...
Roche (RHHBY) Tecentriq Meets Adjuvant Liver Cancer Study Goal
Zacks via Yahoo Finance· 1 year agoRoche's (RHHBY) phase III IMbrave050 study, evaluating Tecentriq plus Avastin for treating...
Roche's (RHHBY) 2022 Core Earnings Grow, 2023 Outlook Dismal
Zacks via Yahoo Finance· 1 year agoRoche Holding AG’s RHHBY performance in 2022 was pretty average, as the demand for COVID-19 products...
Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down
Zacks via Yahoo Finance· 3 months agoRoche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in...